First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL

NCT05569720 | Completed Phase 1 DMC

• 1 other identifier: APTABOLUS
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

The main objective of the study is to assess the tolerability and safety of ApTOLL administration when comparing intravenous infusion vs. bolus intravenous injection, in healthy volunteers. Pharmacokinetic profile of ApTOLL will be also analysed as secondary objective of the study.

Conditions

Stroke

Outcome Measures

Primary Outcomes (1)

• Adverse Events

  To evaluate the safety and tolerability between different ways of ApTOLL administration: intravenous infusion versus bolus intravenous injection, and pharmacokinetic characteristics of ApTOLL in healthy volunteers after single dose administration in fasting conditions.

  day 1 to day 28

Study Arms (1)

ApTOLL treatment

EXPERIMENTAL

Volunteers will receive a dose of ApTOLL of 0.1mg/kg administered intravenously as slow infusion one day and as a single bolus intravenous injection the second day. In a third and last admission day, volunteers will receive a dose of ApTOLL of 0.2mg/kg administered as a single bolus intravenous injection.

Drug: ApTOLL

Interventions

ApTOLL DRUG

ApTOLL will be administered as follows: * Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion. * Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection. * Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection.

ApTOLL treatment

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female (with no possibility to become pregnant (hysterectomized or menopausal women)) subjects who give their written consent to participate in the study.
• Aged from 18 to 55.
• No clinically significant organic or psychic conditions.
• No clinically significant abnormalities in medical records and physical examination.
• No clinically significant abnormalities in haematology, coagulation, biochemistry, serology and urinalysis .
• No clinically significant abnormalities in vital signs and electrocardiogram.

You may not qualify if:

• Subjects affected by an organic or psychic condition.
• Subjects who have received prescribed pharmacological treatment in the last 15 days or any kind of medication in the 48 hours prior to receiving the study medication
• Subjects with body mass index (weight (kg)/height2 (m2)) outside the 18.5-30.0 range.
• History of sensitivity to any drug.
• Positive drug screening (for cannabis, opiates, cocaine and amphetamines).
• Smoker.
• Daily consumers of alcohol and/or acute alcohol poisoning in the last week.
• Having donated blood in the last month before start of the study.
• Participation in another study with administration of investigational drugs in the previous 3 months (if the study was conducted with drug substances marketed in Spain, a period of at least 1 month or 5 half lives, what is longer, will be considered).
• Inability to follow the instructions or collaborate during the study.

Sponsors & Collaborators

• aptaTargets S.L.: lead
• Centro para el Desarrollo Tecnológico Industrial: collaborator

Study Sites (1)

Clinical Pharmacology Department. Hospital Universitario de La Princesa

Madrid, 28006, Spain

Location

Related Publications (3)

• Hernandez-Jimenez M, Martin-Vilchez S, Ochoa D, Mejia-Abril G, Roman M, Camargo-Mamani P, Luquero-Bueno S, Jilma B, Moro MA, Fernandez G, Pineiro D, Ribo M, Gonzalez VM, Lizasoain I, Abad-Santos F. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. Mol Ther Nucleic Acids. 2022 Mar 9;28:124-135. doi: 10.1016/j.omtn.2022.03.005. eCollection 2022 Jun 14.

  PMID: 35402075 BACKGROUND

• Fernandez G, Moraga A, Cuartero MI, Garcia-Culebras A, Pena-Martinez C, Pradillo JM, Hernandez-Jimenez M, Sacristan S, Ayuso MI, Gonzalo-Gobernado R, Fernandez-Lopez D, Martin ME, Moro MA, Gonzalez VM, Lizasoain I. TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models. Mol Ther. 2018 Aug 1;26(8):2047-2059. doi: 10.1016/j.ymthe.2018.05.019. Epub 2018 Jun 15.

  PMID: 29910175 BACKGROUND

• Hernandez-Jimenez M, Martin-Vilchez S, Mejia-Abril G, Roman M, Luquero-Bueno S, Pineiro D, Ribo M, Abad-Santos F, Ochoa D. Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers. Mol Ther Nucleic Acids. 2024 Dec 21;36(1):102435. doi: 10.1016/j.omtn.2024.102435. eCollection 2025 Mar 11.

  PMID: 39897575 DERIVED

MeSH Terms

Conditions

Stroke

Interventions

TLR4 antagonist ApTOLL

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Macarena Hernández, PhD

  aptaTargets S.L.

  STUDY DIRECTOR

• Dolores Ochoa, MD, PhD

  Hospital Universitario La Princesa

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2022
• First Posted: October 6, 2022
• Study Start: April 25, 2022
• Primary Completion: June 24, 2022
• Study Completion: June 24, 2022
• Last Updated: October 6, 2022

Record last verified: 2022-10

Locations

ES (1)